A phase II/III, randomized, open-label, multicenter study of BI 907828 compared to doxorubicin in the first-line treatment of patients with advanced dedifferentiated liposarcoma (DDLPS): Brightline-1-MedSci.cn

A phase II/III, randomized, open-label, multicenter study of BI 907828 compared to doxorubicin in the first-line treatment of patients with advanced dedifferentiated liposarcoma (DDLPS): Brightline-1

Offski, PS; Schuetze, S; Broto, JM; Wagner, AJ; Bauer, S; Chen, V; Teufel, M; Lucarelli, A; Lahmar, M; Maki, RG

JOURNAL OF CLINICAL ONCOLOGY, 2022; 40 (16):

科室
- - 订阅+
  - 更多科室
工具
服务